HC Wainwright & Co. Adjusts LifeMD Price Target to $6.00
HC Wainwright & Co. has lowered its price target for LifeMD, Inc. from $9.00 to $6.00 per share.
Stocks · News reference
LifeMD, Inc. has entered into an arrangement with Eli Lilly and Company to allow its affiliated pharmacy to directly dispense and ship Lilly's self-pay GLP-1 medications to eligible patients.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
HC Wainwright & Co. has lowered its price target for LifeMD, Inc. from $9.00 to $6.00 per share.
Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out today. SBC
LifeMD updated its full-year 2026 revenue outlook, reducing the forecast to a range of $188 million to $191 million.
LifeMD reported its third-quarter 2026 financial results, highlighting a revenue of $44.6 million and an adjusted EBITDA loss of approximately $0.4 million.
The Law Offices of Frank R. Cruz has launched an investigation into potential securities fraud at LifeMD, Inc. following a 14.56% decline in the company's stock price.